Provider review
Henry Meds tirzepatide review
What Henry Meds charges, what is included, who prescribes, which pharmacy fills it, where it operates — and how much of that we confirmed ourselves rather than took from the website.
Read on Henry Meds’s own pages on November 20, 2026: no injectable tirzepatide price printed. It scores 50/100 under our written v4.1 scoring guide, #18 of 22 programs scored.
What is distinctive about this programme
The omission that matters most
Henry Meds offers tirzepatide as oral tablets only. There is no injectable tirzepatide programme. For a patient searching specifically for compounded tirzepatide, that is the single most important fact on this page, and it is easy to miss on a platform that lists tirzepatide prominently.
No trial has tested an oral or sublingual compounded GLP-1. At $349 a month, the oral tirzepatide programme is priced above brand Zepbound direct from LillyDirect at $299 and well above the approved oral orforglipron at $149.
Paid-in-full pricing moves sharply
Injectable semaglutide is $297 month-to-month, $247 on six months paid in full ($1,482 upfront) and $197 on twelve months ($2,364 upfront). That is a 34% reduction for the twelve-month commitment, and the upfront figures are substantial.
Liraglutide follows the same shape: $179 month-to-month, $149 on six months ($894), $119 on twelve ($1,428). Liraglutide is a daily injection and is meaningfully less effective than semaglutide or tirzepatide — the SCALE programme reported roughly 8% mean reduction against 14.9% for semaglutide and around 20.9% for tirzepatide. It is rarely the right choice on effectiveness, and here it is not dramatically cheaper either.
Sublingual as the entry point
At $179, sublingual semaglutide tablets or drops are Henry Meds' lowest-priced offering. The evidence caution applies in full: no trial has tested a compounded sublingual GLP-1, and how much drug reaches the bloodstream is unpublished.
Show this figure as a table
| Item | Value | Evidence |
|---|---|---|
| Semaglutide sublingual | $179 | Provider-reported |
| Liraglutide injectable | $179 | Provider-reported |
| Semaglutide oral / ODT | $249 | Provider-reported |
| Semaglutide injectable | $297 | Provider-reported |
| Tirzepatide oral / ODT | $349 | Provider-reported |
Where it holds up
- Paid-in-full plans cut the injectable semaglutide rate substantially, to $197 on twelve months
- Offers liraglutide for patients who need a daily option
- Range of formulations at different price points
Where it does not
- No injectable tirzepatide at all — oral tablets only
- Oral tirzepatide at $349 costs more than brand Zepbound direct at $299
- Sublingual and oral formats have no trial evidence
- Twelve-month rates require $1,428 to $2,364 upfront
- Figures are third-party reported and not yet captured by us
| Field | Position |
|---|---|
| Membership | Separate and required |
| Dose structure | Escalates with dose or not established |
| Lowest captured figure | $179/mo, month-to-month |
| Evidence status | Third-party reported, pending our own capture |
| Pharmacy named to us | No — provider-reported only |
| Category | Points |
|---|---|
| Pricing transparency | 20 |
| Total annual cost | 20 |
| Clinical oversight | 15 |
| Pharmacy transparency | 15 |
| Support | 10 |
| Regulatory disclosure | 10 |
| Accessibility | 10 |
Pricing, all-in
Plan total and monthly equivalent are calculated by us from the provider's published figures, using the same formula applied to every provider on this site. A price is only a price once the required fees are inside it.
| Provider | Program | Formulation | Dose coverage | Medication | Required fees | All-in monthly | Price type | Evidence | Captured |
|---|---|---|---|---|---|---|---|---|---|
| Henry Meds | prepaid | compounded oral / ODT | not recorded | $349 | not verified | $349 | Commitment tier | Provider-reported | 2026-07-06 |
| Henry Meds | month_to_month | compounded injectable | not recorded | $297 | not verified | $297 | Recurring | Provider-reported | 2026-07-06 |
| Henry Meds | month_to_month | compounded sublingual | not recorded | $179 | not verified | $179 | Recurring | Provider-reported | 2026-07-06 |
| Henry Meds | prepaid | compounded oral / ODT | not recorded | $249 | not verified | $249 | Commitment tier | Provider-reported | 2026-07-06 |
| Henry Meds | month_to_month | compounded injectable | not recorded | $179 | not verified | $179 | Recurring | Provider-reported | 2026-07-06 |
How this sits against the market
The July 2026 all-provider chart that stood here has been retired. Current first-party prices for 28 compounded tirzepatide programs (read October 15, 2026; NexLife November 20, 2026) are on the price index.
Show this figure as a table
| Component | Amount |
|---|---|
| Medication | not captured |
| Membership | not captured |
| Shipping | not captured |
| Dose surcharge | not captured |
| Consultation | not captured |
| Labs | not captured |
| All-in total | not captured |
| Cost component | Inside the advertised figure? | Charged anyway? |
|---|---|---|
| Medication | yes | yes |
| Membership or program fee | no | not verified |
| Shipping | no | not verified |
| Higher-dose surcharge | no | not verified |
| Initial consultation | no | not verified |
| Required laboratory work | no | not verified |
| Cancellation or restocking terms | no | not verified |
This chart stays empty until two or more dated captures exist. Historical values are never estimated or backfilled from a provider's current page.
Show this figure as a table
| Item | This provider | Category median |
|---|---|---|
| All-in monthly | not captured | not captured |
| Membership fee | not captured | not captured |
| Rubric score | not captured | not captured |
What is included, and what is not
Where it holds up
- nothing verified yet
Where it does not
- nothing verified yet
Where it operates
State availability is verified against the provider's own checkout or a support confirmation, state by state, with a capture date. A provider serving forty states is not nationwide, and we do not describe it that way.
Show this figure as a table
| Status | Records | Share |
|---|---|---|
| Researched and verified | 0 | 0% |
| Not yet researched | 51 | 100% |
Pharmacy and fulfilment
What changed
Show this figure as a table
| No events recorded. |
- no entriesNothing has changed yet because nothing has been published yet. Entries appear here when a verified figure, score or conclusion changes, never for a typo fix.
How this compares to the category
Once enough providers are scored, this section reports where Henry Meds sits against the median for each rubric category, not against a hand-picked competitor.
| Question | Worth | Their answer | Status |
|---|---|---|---|
| Pharmacy traceability and quality disclosures | 15 pts | not verified | Not answered Verification pending |
| Clinical oversight and care continuity | 20 pts | not verified | Not answered Verification pending |
| State access and operational reliability | 10 pts | not verified | Not answered Verification pending |
| Cancellation, billing and support transparency | 10 pts | not verified | Not answered Verification pending |
Questions readers actually ask
Is Henry Meds the cheapest option?
Read on its own page on November 20, 2026: no injectable tirzepatide price printed; oral tirzepatide tablets $1,047 for a 3-month supply ($891 if paid in full).
Is compounded tirzepatide the same as Zepbound?
Henry Meds scores 50/100 under the written v4.1 scoring guide, #18 of 22 programs scored from pages read November 20–21, 2026. Its weakest category is support (0 of 10).
Related on this site
- All provider reviewsProviders
- NexLife Tirzepatide ReviewProviders
- Ro Body Tirzepatide ReviewProviders
- Hims & Hers Tirzepatide ReviewProviders
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- Noom Med Tirzepatide ReviewProviders
- NexLife vs Henry MedsComparisons
- Most Affordable Tirzepatide Online: Verified All-In CostsPillar / Money
Related coverage
GLP-1 Tirzepatide Review. “Henry Meds Tirzepatide Review.” S.J Partners LLC, 2026-07-26. https://glptirzepatidereview.com/providers/henry-meds/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.